Iclusig Net Product Revenue Guidance for 2015
in the Range of $130 Million to $140 Million
Three New Iclusig Clinical Trials Planned to
Begin This Year
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported
financial results for the fourth quarter and full year ended
December 31, 2014 and issued 2015 financial guidance. Additionally,
the Company provided an update on corporate developments and key
objectives for 2015.
“We made solid progress throughout our business during 2014 --
commercializing Iclusig® (ponatinib) and advancing our pipeline,
moving brigatinib into a pivotal trial in patients with refractory
anaplastic lymphoma kinase positive non-small cell lung cancer and
nominating our next drug candidate, AP32788,” said Harvey J.
Berger, M.D., chairman and chief
executive officer of ARIAD. “Additionally, we strengthened our
balance sheet last year with non-dilutive funding from the
agreements with Otsuka Pharmaceutical Co., Ltd. and Bellicum
Pharmaceuticals, Inc. In 2015, our focus is on expanding the global
commercial opportunity for Iclusig and strategically investing in
value-driving clinical initiatives to position the Company for
sustained growth and anticipated profitability in 2018.”
2014 Fourth Quarter and Full-Year
Financial Results
Revenues
- Net product revenues from sales of
Iclusig were $21.4 million for the quarter ended December 31, 2014
and $55.7 million for the year ended December 31, 2014. Net product
revenues for the fourth quarter include Iclusig revenues of $17.0
million in the U.S. and $4.4 million in Europe. Net product
revenues in the fourth quarter represented a 47% increase from the
prior quarter.
- Cumulative shipments of Iclusig to
patients in France totaled $18.3 million through December 31, 2014.
We will record revenue related to cumulative shipments in France
upon completion of pricing and reimbursement negotiations in
France, net of amounts that will be refunded to the French health
authorities as a result of such negotiations, which we anticipate
will be completed in mid-2015.
- License revenues for the fourth quarter
of 2014 were $45.5 million, which includes the impact of payments
from Bellicum Pharmaceuticals, Inc. (Bellicum) under the amended
license agreement signed in October 2014. Of the $50 million in
payments received from Bellicum, $45.2 million is included in
license revenue, while the remaining $4.8 million is included in
other income related to the value of Bellicum common stock returned
to Bellicum.
Net Loss
Quarter Ended December 31, 2014
- Net loss for the fourth quarter ended
December 31, 2014 was $5.7 million, or $0.03 per share, compared to
a net loss of $74.2 million, or $0.40 per share, for the same
period in 2013. The decrease in net loss is primarily due to the
$50 million received from Bellicum in the fourth quarter of 2014,
an increase of $13.2 million in Iclusig product revenue and a
decrease in operating expenses of $8.0 million, reflecting lower
research and development (R&D) expenses, offset in part by an
increase in interest expense of $3.8 million due to our convertible
debt issuance in June 2014.
- R&D expenses were $32.6 million for
the fourth quarter of 2014, a decrease of 9% from the fourth
quarter of 2013, reflecting a decrease in Iclusig clinical-trial
costs, as well as decreased manufacturing and other supporting
costs related to Iclusig. These decreases were offset, in part, by
increases in clinical-trial and related costs for our
investigational ALK+ inhibitor, brigatinib, related to the ongoing
Phase 2 ALTA trial.
- Selling, general and administrative
expenses were $40.4 million for the fourth quarter of 2014, an
increase of 7% from the fourth quarter of 2013, reflecting an
increase in personnel and other expenses in Europe due to the
commercial launch of Iclusig in various European countries in the
second half of 2014.
Year Ended December 31, 2014
- Net loss for the full year 2014 was
$162.6 million, or $0.87 per share, compared to a net loss of
$274.2 million, or $1.49 per share, for the full year 2013.
- These results include an increase in
Iclusig product revenue of $10.5 million and the $50 million
received from Bellicum, as well as a decrease in operating expenses
of $53.4 million in 2014 as compared to 2013, reflecting a
reduction in R&D expenses related to a decrease in
clinical-trial costs, as well as manufacturing and other support
costs related to Iclusig clinical trials, and a decrease in
personnel and related costs reflecting a lower number of R&D
employees in 2014 compared to 2013.
Cash Position
- As of December 31, 2014, cash and cash
equivalents totaled $352.7 million, compared to $237.2 million at
December 31, 2013.
Recent Progress and Key
Objectives
Commercialization of Iclusig®
- In 2014, nearly 800 patients received
Iclusig commercially in the U.S. Approximately 150 new patients
were treated with Iclusig during the fourth quarter of 2014, an
increase of approximately 10% from the third quarter.
- By the end of the fourth quarter, there
were nearly 660 unique prescribers of Iclusig in the U.S., an
increase in the prescriber base of approximately 25% from the third
quarter of 2014.
- In Europe, we are now selling Iclusig
in Germany, the United Kingdom, Austria, the Netherlands, Norway,
Sweden, and Italy. In addition, we are distributing Iclusig to
patients in France prior to pricing and reimbursement approval as
permitted under French regulations.
- Full pricing and reimbursement in
France and other European countries is expected by mid-2015. In
total, we anticipate that Iclusig will be available for sale in 16
European countries by the third quarter of this year.
- In December of 2014, we entered into an
agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for them to
commercialize Iclusig in Japan and nine other Asian countries and
to fund agreed-upon future clinical development in those countries.
We anticipate filing of the Japanese New Drug Application for
Iclusig in the second half of 2015.
Iclusig Clinical Development
- Three new Iclusig clinical trials are
planned to begin in 2015, two of which will evaluate Iclusig in
earlier lines of treatment, as follows:
- A randomized, Phase 3 trial in
approximately 500 patients with chronic-phase chronic myeloid
leukemia (CP-CML) who have experienced treatment failure after
imatinib therapy.
- A dose-ranging trial of Iclusig in
approximately 450 patients with CP-CML who have become resistant to
at least two prior TKIs.
- An early-switch trial of Iclusig in
approximately 1,000 patients with CP-CML in the United Kingdom
(known as the SPIRIT3 trial) – an investigator-sponsored trial
(IST).
- Additionally, 10 ISTs in the ponatinib
program are open to patient enrollment, and three additional ISTs
are pending regulatory or institutional review board approval.
Advancing Brigatinib
- Brigatinib received Breakthrough
Therapy designation from the U.S. Food and Drug Administration in
2014, which may accelerate its regulatory approval timeline.
Brigatinib is currently being evaluated in the global, Phase 2
pivotal ALTA trial that is anticipated to form the basis for its
initial regulatory approval. We are on track to achieve full
patient enrollment in the ALTA trial in the third quarter of 2015
and to file for approval of brigatinib in the U.S. next year.
- We recently announced plans to secure a
broad partnership in 2015 to co-develop and co-commercialize
brigatinib. We expect that such a partnership will leverage our
existing infrastructure and capabilities, as well as support a
randomized, first-line trial of brigatinib vs. crizotinib in
anaplastic lymphoma kinase positive (ALK+) non-small cell lung
cancer (NSCLC). A partnership may also support the exploration of
new combination therapies in lung cancer that include brigatinib
with other approved and unapproved medicines.
- We anticipate presenting updates from
the ongoing Phase 1/2 clinical trial of brigatinib at the 2015
European Lung Cancer Conference and the American Society of
Clinical Oncology meetings later this year. Additionally, we expect
to present preliminary data from the brigatinib ALTA trial in the
second half of 2015.
Expanding the Pipeline
- At the end of 2014, we nominated our
next internally discovered development candidate, AP32788. This
orally active TKI has a unique profile against a validated class of
mutated targets in NSCLC and certain other solid tumors and may
address an important unmet medical need.
- We expect to file an investigational
new drug (IND) application for AP32788 this year and to begin a
Phase 1/2 proof-of-concept trial in 2016. This will be our third
IND filing of an internally discovered oncology development
candidate in the past eight years.
- This complements our earlier discovery
of ridaforolimus, which is being developed by Medinol Ltd. for use
in drug-eluting stents (BioNIR) and is in global pivotal trials,
and rimiducid (AP1903), which is being developed by Bellicum for
use in novel cellular immunotherapies and is in Phase 1/2 clinical
trials.
2015 Financial Guidance
- Net product revenues from sales of
Iclusig are expected to be in the range of $130 million to $140
million. This guidance includes sales of Iclusig in the U.S.,
Europe, and other select countries where ARIAD has distributorships
in place.
- R&D expenses are expected to be in
the range of $185 million to $195 million, reflecting increased
development activities for Iclusig, brigatinib, and AP32788, as
well as ongoing discovery research efforts. Expenses related to
Iclusig represent approximately 50% of total R&D expenses and
include the three new planned trials to begin this year, as well as
all ongoing trials. Expenses related to brigatinib represent
approximately 35% of total R&D expenses and include the two
ongoing trials and NDA-enabling pre-clinical studies.
- Selling, general and administrative
expenses are expected to be in the range of $135 million to $145
million, of which approximately 55% represents U.S. and EU
commercial operations and supporting activities for Iclusig.
- Non-cash expenses are expected to be in
the range of $45 million to $50 million, consisting primarily of
stock-based compensation and depreciation and amortization
expenses.
- Cash and cash equivalents at December
31, 2015 is expected to be at least $200 million.
Upcoming Investor Meetings
ARIAD management will be making corporate presentations at the
following investor conferences:
- RBC Capital Markets’ Healthcare
Conference, New York City, February 25, 2015
- Cowen and Company Healthcare
Conference, Boston, March 2, 2015
Today’s Conference Call at 8:30 a.m. ET
We will hold a live webcast and conference call of our fourth
quarter/year-end 2014 financial results this morning at 8:30 a.m.
ET. The live webcast can be accessed by visiting the investor
relations section of the Company’s website at
http://investor.ariad.com. The call can be accessed by dialing
888-771-4371 (domestic) or 847-585-4405 (international) five
minutes prior to the start time and providing the pass code
38869071. A replay of the call will be available on the ARIAD
website approximately two hours after completion of the call and
will be archived for three weeks.
About Iclusig® (ponatinib) tablets
Iclusig is a kinase inhibitor. The primary target for Iclusig is
BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic
myeloid leukemia (CML) and Philadelphia-chromosome positive acute
lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using
ARIAD’s computational and structure-based drug-design platform
specifically to inhibit the activity of BCR-ABL. Iclusig targets
not only native BCR-ABL but also its isoforms that carry mutations
that confer resistance to treatment, including the T315I mutation,
which has been associated with resistance to other approved
TKIs.
Iclusig is approved in the U.S., EU, Australia and
Switzerland.
In the U.S., Iclusig is a kinase inhibitor indicated for
the:
- Treatment of adult patients with
T315I-positive chronic myeloid leukemia (chronic phase, accelerated
phase, or blast phase) or T315I-positive Philadelphia chromosome
positive acute lymphoblastic leukemia (Ph+ ALL).
- Treatment of adult patients with
chronic phase, accelerated phase, or blast phase chronic myeloid
leukemia or Ph+ ALL for whom no other tyrosine kinase inhibitor
(TKI) therapy is indicated.
IMPORTANT SAFETY INFORMATION, INCLUDING THE BOXED
WARNINGWARNING: VASCULAR OCCLUSION, HEART FAILURE, and
HEPATOTOXICITY
See full prescribing information for complete boxed
warning
- Vascular Occlusion: Arterial and
venous thrombosis and occlusions have occurred in at least 27% of
Iclusig treated patients, including fatal myocardial infarction,
stroke, stenosis of large arterial vessels of the brain, severe
peripheral vascular disease, and the need for urgent
revascularization procedures. Patients with and without
cardiovascular risk factors, including patients less than 50 years
old, experienced these events. Monitor for evidence of
thromboembolism and vascular occlusion. Interrupt or stop Iclusig
immediately for vascular occlusion. A benefit risk consideration
should guide a decision to restart Iclusig therapy.
- Heart Failure, including fatalities,
occurred in 8% of Iclusig-treated patients. Monitor cardiac
function. Interrupt or stop Iclusig for new or worsening heart
failure.
- Hepatotoxicity, liver failure and
death have occurred in Iclusig-treated patients. Monitor hepatic
function. Interrupt Iclusig if hepatotoxicity is
suspected.
Vascular Occlusion: Arterial and venous thrombosis and
occlusions, including fatal myocardial infarction, stroke, stenosis
of large arterial vessels of the brain, severe peripheral vascular
disease, and the need for urgent revascularization procedures have
occurred in at least 27% of Iclusig-treated patients from the phase
1 and phase 2 trials. Iclusig can also cause recurrent or
multi-site vascular occlusion. Overall, 20% of Iclusig-treated
patients experienced an arterial occlusion and thrombosis event of
any grade. Fatal and life-threatening vascular occlusion has
occurred within 2 weeks of starting Iclusig treatment and in
patients treated with average daily dose intensities as low as 15
mg per day. The median time to onset of the first vascular
occlusion event was 5 months. Patients with and without
cardiovascular risk factors have experienced vascular occlusion
although these events were more frequent with increasing age and in
patients with prior history of ischemia, hypertension, diabetes, or
hyperlipidemia. Interrupt or stop Iclusig immediately in patients
who develop vascular occlusion events.
Heart Failure: Fatal and serious heart failure or left
ventricular dysfunction occurred in 5% of Iclusig-treated patients
(22/449). Eight percent of patients (35/449) experienced any grade
of heart failure or left ventricular dysfunction. Monitor patients
for signs or symptoms consistent with heart failure and treat as
clinically indicated, including interruption of Iclusig. Consider
discontinuation of Iclusig in patients who develop serious heart
failure.
Hepatotoxicity: Iclusig can cause hepatotoxicity,
including liver failure and death. Fulminant hepatic failure
leading to death occurred in an Iclusig-treated patient within one
week of starting Iclusig. Two additional fatal cases of acute liver
failure also occurred. The fatal cases occurred in patients with
blast phase CML (BP-CML) or Philadelphia chromosome positive acute
lymphoblastic leukemia (Ph+ ALL). Severe hepatotoxicity occurred in
all disease cohorts. Iclusig treatment may result in elevation in
ALT, AST, or both. Monitor liver function tests at baseline, then
at least monthly or as clinically indicated. Interrupt, reduce or
discontinue Iclusig as clinically indicated.
Hypertension: Treatment-emergent hypertension (defined as
systolic BP≥140 mm Hg or diastolic BP≥90 mm Hg on at least one
occasion) occurred in 67% of patients (300/449). Eight patients
treated with Iclusig (2%) experienced treatment-emergent
symptomatic hypertension as a serious adverse reaction, including
one patient (<1%) with hypertensive crisis. Patients may require
urgent clinical intervention for hypertension associated with
confusion, headache, chest pain, or shortness of breath. In 131
patients with Stage 1 hypertension at baseline, 61% (80/131)
developed Stage 2 hypertension. Monitor and manage blood pressure
elevations during Iclusig use and treat hypertension to normalize
blood pressure. Interrupt, dose reduce, or stop Iclusig if
hypertension is not medically controlled.
Pancreatitis: Clinical pancreatitis occurred in 6%
(28/449) of patients (5% Grade 3) treated with Iclusig.
Pancreatitis resulted in discontinuation or treatment interruption
in 6% of patients (25/449). The incidence of treatment-emergent
lipase elevation was 41%. Check serum lipase every 2 weeks for the
first 2 months and then monthly thereafter or as clinically
indicated. Consider additional serum lipase monitoring in patients
with a history of pancreatitis or alcohol abuse. Dose interruption
or reduction may be required. In cases where lipase elevations are
accompanied by abdominal symptoms, interrupt treatment with Iclusig
and evaluate patients for pancreatitis. Do not consider restarting
Iclusig until patients have complete resolution of symptoms and
lipase levels are less than 1.5 x ULN.
Neuropathy: Peripheral and cranial neuropathy have
occurred in Iclusig-treated patients. Overall, 13% (59/449) of
Iclusig-treated patients experienced a peripheral neuropathy event
of any grade (2%, grade 3/4). In clinical trials, the most common
peripheral neuropathies reported were peripheral neuropathy (4%,
18/449), paresthesia (4%, 17/449), hypoesthesia (2%, 11/449), and
hyperesthesia (1%, 5/449). Cranial neuropathy developed in 1%
(6/449) of Iclusig-treated patients (<1% grade 3/4). Of the
patients who developed neuropathy, 31% (20/65) developed neuropathy
during the first month of treatment. Monitor patients for symptoms
of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia,
discomfort, a burning sensation, neuropathic pain or weakness.
Consider interrupting Iclusig and evaluate if neuropathy is
suspected.
Ocular Toxicity: Serious ocular toxicities leading to
blindness or blurred vision have occurred in Iclusig-treated
patients. Retinal toxicities including macular edema, retinal vein
occlusion, and retinal hemorrhage occurred in 3% of Iclusig-treated
patients. Conjunctival or corneal irritation, dry eye, or eye pain
occurred in 13% of patients. Visual blurring occurred in 6% of the
patients. Other ocular toxicities include cataracts, glaucoma,
iritis, iridocyclitis, and ulcerative keratitis. Conduct
comprehensive eye exams at baseline and periodically during
treatment.
Hemorrhage: Serious bleeding events, including
fatalities, occurred in 5% (22/449) of patients treated with
Iclusig. Hemorrhagic events occurred in 24% of patients. The
incidence of serious bleeding events was higher in patients with
accelerated phase CML (AP-CML), BP-CML, and Ph+ ALL. Most
hemorrhagic events, but not all occurred in patients with grade 4
thrombocytopenia. Interrupt Iclusig for serious or severe
hemorrhage and evaluate.
Fluid Retention: Serious fluid retention events occurred
in 3% (13/449) of patients treated with Iclusig. One instance of
brain edema was fatal. In total, fluid retention occurred in 23% of
the patients. The most common fluid retention events were
peripheral edema (16%), pleural effusion (7%), and pericardial
effusion (3%). Monitor patients for fluid retention and manage
patients as clinically indicated. Interrupt, reduce, or discontinue
Iclusig as clinically indicated.
Cardiac Arrhythmias: Symptomatic bradyarrhythmias that
led to a requirement for pacemaker implantation occurred in 1%
(3/449) of Iclusig-treated patients. Advise patients to report
signs and symptoms suggestive of slow heart rate (fainting,
dizziness, or chest pain). Supraventricular tachyarrhythmias
occurred in 5% (25/449) of Iclusig-treated patients. Atrial
fibrillation was the most common supraventricular tachyarrhythmia
and occurred in 20 patients. For 13 patients, the event led to
hospitalization. Advise patients to report signs and symptoms of
rapid heart rate (palpitations, dizziness). Interrupt Iclusig and
evaluate.
Myelosuppression: Severe (grade 3 or 4) myelosuppression
occurred in 48% (215/449) of patients treated with Iclusig. The
incidence of these events was greater in patients with AP-CML,
BP-CML and Ph+ ALL than in patients with CP-CML. Obtain complete
blood counts every 2 weeks for the first 3 months and then monthly
or as clinically indicated, and adjust the dose as recommended.
Tumor Lysis Syndrome: Two patients (<1%) with advanced
disease (AP-CML, BP-CML, or Ph+ ALL) treated with Iclusig developed
serious tumor lysis syndrome. Hyperuricemia occurred in 7% (30/449)
of patients overall; the majority had CP-CML (19 patients). Due to
the potential for tumor lysis syndrome in patients with advanced
disease, ensure adequate hydration and treat high uric acid levels
prior to initiating therapy with Iclusig.
Compromised Wound Healing and Gastrointestinal
Perforation: Since Iclusig may compromise wound healing,
interrupt Iclusig for at least 1 week prior to major surgery.
Serious gastrointestinal perforation (fistula) occurred in one
patient 38 days post-cholecystectomy.
Embryo-Fetal Toxicity: Iclusig can cause fetal harm. If
Iclusig is used during pregnancy, or if the patient becomes
pregnant while taking Iclusig, the patient should be apprised of
the potential hazard to the fetus. Advise women to avoid pregnancy
while taking Iclusig.
Most common non-hematologic adverse reactions: (≥20%)
were hypertension, rash, abdominal pain, fatigue, headache, dry
skin, constipation, arthralgia, nausea, and pyrexia. Hematologic
adverse reactions included thrombocytopenia, anemia, neutropenia,
lymphopenia, and leukopenia.
Please see the full U.S. Prescribing Information
for Iclusig, including the Boxed Warning, for additional
important safety information.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
This press release contains “forward-looking statements”
including, but not limited to, updates on clinical, preclinical and
regulatory developments and commercialization plans for our
products and product candidates and financial guidance for 2015.
Forward-looking statements are based on management's good faith
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events,
timing and performance to differ materially from those expressed or
implied by such statements. These factors, risks and uncertainties
include, but are not limited to, our ability to meet anticipated
clinical trial commencement, enrollment and completion dates for
our products and product candidates and to move new development
candidates into the clinic; our ability to secure a partnership for
AP26113; difficulties or delays in obtaining regulatory and pricing
and reimbursement approvals to market our products; our ability to
successfully commercialize and generate profits from sales of
Iclusig; competition from alternative therapies; our reliance on
the performance of third-party manufacturers and specialty
pharmacies for the distribution of Iclusig; the occurrence of
adverse safety events with our products and product candidates;
preclinical data and early-stage clinical data that may not be
replicated in later-stage clinical studies; the costs associated
with our research, development, manufacturing and other activities;
the conduct and results of preclinical and clinical studies of our
product candidates; the adequacy of our capital resources and the
availability of additional funding; patent protection and
third-party intellectual property claims; risks related to key
employees, markets, economic conditions, health care reform, prices
and reimbursement rates; and other risk factors detailed in the
Company's public filings with the U.S. Securities and Exchange
Commission. The information contained in this press release is
believed to be current as of the date of original issue. After the
date of this document, the Company does not intend to update any of
the forward-looking statements to conform these statements to
actual results or to changes in the Company's expectations, except
as required by law.
ARIAD PHARMACEUTICALS, INC. AND
SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS
(Unaudited)
In thousands, except
per share data Three Months Ended
December 31,
Year Ended
December 31,
2014 2013
2014 2013 Revenue:
Product revenue, net $ 21,349 $ 8,281 $ 55,720 $ 45,238 License and
other revenue 45,486 72 49,692 323 Total
revenue 66,835 8,353 105,412 45,561 Operating
expenses: Cost of product revenue 947 8,699 5,224 9,612 Research
and development 32,645 35,824 120,593 162,900 Selling, general and
administrative 40,379 37,637 139,790 146,615
Total operating expenses 73,791 82,160 265,607
319,127 Other income (expense), net 1,636 (172 ) (1,777 )
(153 ) Provision for income taxes 251 184 630
439 Net loss $ (5,751
)
$ (74,163
)
$ (162,602 ) $ (274,158 ) Net loss per common share: -- basic and
diluted $ (0.03 ) $ (0.40
)
$ (0.87 ) $ (1.49 ) Weighted-average number of shares of common
stock outstanding: -- basic and diluted 187,226 185,699 186,835
183,575
CONDENSED CONSOLIDATED BALANCE SHEET
INFORMATION
In thousands
December 31,
2014
December 31,
2013
Cash and cash equivalents $ 352,688 $ 237,179 Total assets $
603,870 $ 370,894 Total liabilities $ 523,069 $ 185,377
Stockholders’ equity $ 80,801 $ 185,517
CONDENSED CONSOLIDATED STATEMENT OF
CASH FLOWS INFORMATION
In thousands Year Ended
December 31,
2014 2013 Net cash used
in operating activities $ (57,794) $ (221,882 ) Net cash provided
by (used in) investing activities 1,981 26,138 Net cash provided by
financing activities 171,060 313,584 Effect of exchange rates on
cash 262 (40) Net increase in cash and cash equivalents $
115,509 $ 117,800
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor MediaLiza Heapes,
617-621-2315Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From May 2024 to Jun 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Jun 2023 to Jun 2024